Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1068 of 6351
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that d…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo shows promise for tough liver cancer
Disease control CompletedThis is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC. Locally advanced or metastatic HCC is defined as disease that is not amenable to surgical and/or locoregional therapies. Subjects mu…
Phase 2 • Sponsor: David Hsieh • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Double-Drug attack shows promise for tough prostate cancer
Disease control OngoingThis randomized phase II trial studies how well abiraterone acetate and antiandrogen therapy, with or without cabazitaxel and prednisone, work in treating patients with castration-resistant prostate cancer previously treated with docetaxel that has spread to other parts of the bo…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for Hard-to-Treat CLL
Disease control OngoingThis is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug nivolumab takes on EBV-Linked tumors in new trial
Disease control Recruiting nowBackground: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivoluma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for Hard-to-Treat lung cancer? osimertinib trial launches
Disease control Recruiting nowThis phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blo…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immunotherapy before bladder surgery shows promise in early trial
Disease control OngoingThe purpose of this study is to test if immunotherapy with nivolumab alone or in combination with ipilimumab is safe and does not delay the planned bladder cancer surgery. The investigators want to see if treatment with these drugs prior to surgery may decrease the size of the bl…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo therapy aims to shrink lymphoma with less radiation
Disease control CompletedCombined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dose will be adapted for low-responders. Primary Objective: Evaluation of the rate of metabolic CR after low-dose involved site radiotherapy …
Phase 2 • Sponsor: Heidelberg University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could a vitamin supplement boost male fertility and pregnancy odds?
Disease control CompletedInfertility is a worldwide problem and about 10%-15% of all couples will be affected by the inability to have children. In approximately 50% of infertile couples a male factor is involved. Male infertility is of multifactorial origin. In the past decade, the role of oxidative str…
Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New heart valve fix without surgery shows promise for High-Risk patients
Disease control OngoingThis study will evaluate the safety of the Cardiovalve Transfemoral Mitral Valve System with its associated procedure, and observe the device performance in reducing mitral regurgitation. Data collected in this clinical study will include 30-day safety and performance, and long-t…
Sponsor: Cardiovalve Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Eye-Tracking goggles could spot hidden brain injuries
Diagnosis Stopped earlyThis study aims to determine the validity and safety of disparity driven vergence using a portable goggle system (I-PAS) using a pseudorandom ternary sequence of frequencies for testing.
Sponsor: University of Miami • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
Double transplant trial aims to fix lungs and blood in one go
Disease control Recruiting nowThe purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
Phase 1/2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Experimental drug combo shows promise for Tough-to-Treat leukemia
Disease control OngoingThis phase Ib/II trial studies the side effects and best dose of pevonedistat and to see how well it works in combination with cytarabine and idarubicin in treating patients with acute myeloid leukemia. Pevonedistat may stop the growth of cancer cells by blocking some of the enzy…
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail shows promise in battling blood cancer
Disease control OngoingThe purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New kidney drug shows promise in FSGS trial
Disease control CompletedTo determine the long-term nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with primary and genetic focal segmental glomerulosclerosis (FSGS).
Phase 3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis randomized phase II trial studies how well cabozantinib s-malate and nivolumab work in treating patients with endometrial cancer that has come back (recurrent) or spread to other places in the body (advanced or metastatic). Cabozantinib may stop the growth of tumor cells by …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 02:00 UTC
-
New male pill aims to stop sperm production
Disease control CompletedThis is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to evaluate the spermatogenesis suppression after oral administration of Dimethandrolone Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.
Phase 2 • Sponsor: Premier Research • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a new pill tame high cholesterol?
Disease control CompletedThis is a randomized, double-blind, placebo-controlled, multicenter, multiple ascending dose (MAD) study to evaluate the safety and tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of HTD1801 in overweight to obese adults with hypercholesterolemia. There were…
Phase 1/2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
A drop of blood may reveal hidden prenatal alcohol exposure
Knowledge-focused CompletedThe objective of the study is to validate epigenetic changes as biomarkers in a prospective sampling of newborn blood samples collected at birth (umbilical cord blood) and during routine screening (heel stick blood) in newborns concurrently tested for alcohol exposure levels by P…
Sponsor: CAMC Health System • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Your Tumor's DNA might predict immunotherapy success
Knowledge-focused Recruiting nowThis study is designed to identify the predictive biomarker for immunotherapy using patient samples (tumor tissue, blood, fecal material) who treated with immune checkpoint inhibitor.
Sponsor: Samsung Medical Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC